The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

Joseph Murphy; R. Wright; Ihor Gussak; Brent Williams; Robert Daly; Valerie Cain; Henry Pieniaszek; Sherwin Sy; William Ebling; Kristen Simonson; Racehl Wilcox; Stephen Kopecky

doi:10.2165/00129784-200303020-00004

$Introduction: Intravenous platelet glycoprotein (GP) IIb/IIIa receptor inhibitors have a significant beneficial impact on the outcomes of patients undergoing high-risk coronary interventions and in the stabilization of patients with unstable angina pectoris refractory to conventional medical treatment. The role of long-term treatment with oral platelet GP IIb/IIIa receptor inhibitors in patients with coronary artery disease is unproven. This study examined the dose-response effect on inhibition of platelet aggregation by roxifiban (DMP754), a novel oral platelet GP IIb/IIIa receptor inhibitor, and its safety and tolerability in patients with a history of chronic stable angina pectoris.$

References (41)

K. Ault, C. Cannon, Jane Mitchell, J. McCahan, R. Tracy, W. Novotny, J. Reimann, E. Braunwald (1999)

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.

Journal of the American College of Cardiology, 33 3

M. Quinn, E. Plow, E. Topol (2002)

Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?

Circulation: Journal of the American Heart Association, 106

C. Cannon, C. Mccabe, R. Wilcox, A. Langer, A. Caspi, Peter Berink, J. López-Sendón, J. Toman, A. Charlesworth, R. Anders, J. Alexander, A. Skene, E. Braunwald (2000)

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

Circulation, 102 2

D. Phillips, Willy Teng, A. Arfsten, L. Nannizzi-Alaimo, M. White, C. Longhurst, S. Shattil, A. Randolph, J. Jakubowski, L. Jennings, R. Scarborough (1997)

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

Circulation, 96 5

S. Mousa, M. Forsythe, W. Lorelli, J. Bozarth, C. Xue, J. Wityak, T. Sielecki, Rick Olson, W. DeGrado, R. Kapil, M. Hussain, R. Wexler, M. Thoolen, T. Reilly (1996)

Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754: receptor binding affinity and specificity

Coronary Artery Disease, 7

S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

The New England journal of medicine, 345 7

S. Mousa, R. Kapil, D. Mu (1999)

Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.

Arteriosclerosis, thrombosis, and vascular biology, 19 10

C. Hamm, C. Heeschen, B. Goldmann, A. Vahanian, J. Adgey, C. Miguel, W. Rutsch, J. Berger, J. Kootstra, M. Simoons (1999)

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

The New England journal of medicine, 340 21

(1994)

Antiplatelet Trialists’ Collaborationprevention of death, myocardial infarction, and stroke by prolonged antiplateiet therapy in various categories of patients

BMJ, 308

C. Cannon (2000)

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

Clinical Cardiology, 23

W.W. O’Neill, P. Serruys, M. Knudtson (2000)

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization

N Engi J Med, 342

A. Frelinger, M. Furman, Lori Krueger, M. Barnard, A. Michelson (2001)

Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation

Circulation: Journal of the American Heart Association, 104

B. Bednar, J. Cook, M. Holahan, M. Cunningham, Patricia Jumes, R. Bednar, G. Hartman, R. Gould (1999)

Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa

Blood, 94

(2004)

Millennium Pharmaceuticals, Inc.

Personalized medicine, 1 1

N. Kleiman (1999)

Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.

American heart journal, 138 4 Pt 2

K. Peter, M. Schwarz, J. Ylänne, B. Kohler, M. Moser, T. Nordt, P. Salbach, W. Kübler, C. Bode (1998)

Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors

Blood, 92

Epic Investigators (1994)

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

The New England journal of medicine, 330 14

M. Creager (1998)

Results of the CAPRIE trial: efficacy and safety of clopidogrel

Vascular Medicine, 3

D. Seiffert, A. Stern, W. Ebling, R. Rossi, Y. Barrett, R. Wynn, G. Hollis, Bokang He, C. Kieras, D. Pedicord, D. Cromley, T. Hua, R. Stein, R. Daly, A. Sferruzza, H. Pieniaszek, J. Billheimer (2003)

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

Blood, 101 1

W. Tan, D. Moliterno (1999)

Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives.

Cleveland Clinic journal of medicine, 66 10

E. Topol, E. Plow (1993)

Clinical Trials of Platelet Receptor Inhibitors

Thrombosis and Haemostasis, 70

J. Billheimer, I. Dicker, R. Wynn, Jodi Bradley, D. Cromley, Helen Godonis, L. Grimminger, Bokang He, C. Kieras, D. Pedicord, S. Spitz, B. Thomas, N. Zolotarjova, M. Gorko, G. Hollis, R. Daly, A. Stern, D. Seiffert (2002)

Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.

Blood, 99 10

S. Mousa, J. Abulencia, O. McCarty, N. Turner, K. Konstantopoulos (2002)

Comparative Efficacy Between the Glycoprotein IIb/IIIa Antagonists Roxifiban and Orbofiban in Inhibiting Platelet Responses in Flow Models of Thrombosis

Journal of Cardiovascular Pharmacology, 39

R. Altman, L. Carreras, R. Diaz, E. Figueroa, E. Paolasso, J. Parodi, J. Cade, G. Donnan, M. Eadie, T. Gavaghan, E. OSullivan, D. Parkin, Renny Jtg., C. Silagy, H. Vinazzer, F. Zekert, H. Adriaensen, J. Bertrandhardy, M. Bran, J. David, J. Dricot, E. Lavennepardonge, R. Limet, A. Lowenthal, M. Moriau, S. Schapira, P. Smets, J. Symoens, R. Verhaeghe, M. Verstraete, A. Atallah, H. Barnett, R. Batista, J. Blakely, J. Cairns, R. Cote, J. Crouch, G. Evans, J. Findlay, M. Gent, Y. Langlois, J. Leclerc, J. Norris, G. Pineo, P. Powers, R. Roberts, L. Schwartz, J. Sicurella, W. Taylor, P. Théroux, A. Turpie, R. Weisel, J. Cui, L. Liu, J. Pirk, C. Bay, G. Boysen, J. Knudsen, P. Petersen, P. Sørensen, H. Tønnesen, P. Harjola, J. Arcan, B. Balkau, J. Blanchard, J. Boissel, B. Boneu, M. Bousser, M. Brochier, M. Cloarec, G. Cribier, M. Dechavanne, P. Drouin, E. Eschwège, B. Guiraudchaumeil, R. Hugonot, A. Leizorovicz, Y. Loria, L. Michat, J. Mirouze, E. Panak, J. Pasteyer, A. Rascol, L. Revol, M. Roy, J. Sellés, G. Slama, C. Starkman, M. Teule, N. Thibult, M. Verry, F. Albert, K. Andrassy, K. Breddin, R. Eckel, A. Encke, J. Frohlich, B. Hartung, H. Heiss, H. Hess, B. Hofling, D. Krause, G. Latta, H. Linke, D. Loew, R. Lorenz, K. Middleton, G. Novak, M. Oldendorf, N. Pfluger, D. Raithel, R. Reuter, G. Schettler, J. Schnitker, W. Schoop, H. Stiegler, K. Uberla, G. Vogel, M. Weber, I. Welbers, E. Zeitler, G. Arapakis, T. Chan, C. Mok, R. Szabó, N. Misra, K. Reddy, G. FitzGerald, A. Apollonio, F. Balsano, A. Basellini, L. Candelise, M. Catalano, N. Ciavarella, G. Ciuffetti, S. Coccheri, M. Cortellaro, G. Corvi, V. Coto, G. Davı̀, R. Decaterina, T. Diperri, C. Fieschi, R. Gentile, L. Gregoratti, P. Gresele, M. Lavezzari, A. Libretti, B. Magnani, Nenci Gg, G. Pagano, C. Patrono, L. Pedrini, M. Pini, P. Prandoni, F. Romeo, F. Rovelli, G. Rudelli, G. Ruvolo, G. Signorini, G. Tognoni, F. Violi, T. Fujimori, M. Kageyama, T. Katsumura, S. Kitamura, K. Maeda, A. Suzuki, H. Tohgi, S. Uchiyama, H. Utsumi, A. Garcia, A. Algra, Denottolander Gjh., Kupper Ajf., J. Vangijn, H. Hart, L. Kappelle, P. Koudstaal, T. Lemmens, J. Lodder, M. Pannebakker, P. Serruys, A. Vandenbelt, J. Vandermeer, A. Vandervijgh, Verheugt Fwa, G. Veth, J. Dale, K. Johannessen, E. Thaulow, P. Popescu, N. Tiberiu, Aznar Jrd., E. Esmatjes, P. Guiteras, J. Lasierra, P. Lopeztrigo, A. Oriol, L. Pomar, E. Rocha, F. Sanchez, J. Sanchorieger, G. Sanz, Berglund Ulf., C. Blomstrand, M. Boberg, M. Britton, C. Elwin, C. Helmers, J. Holm, L. Janzon, S. Juulmoller, H. Mulec, J. Olsson, S. Persson, G. Rasmanis, A. Rosén, K. Samuelsson, J. Soreff, N. Wahlgren, L. Wallentin, H. Baur, M. Bokslag, A. Bollinger, B. Meier, M. Pfisterer, C. Sitthiamorn, E. Acheson, P. Appleby, A. Asscher, A. Aukland, C. Baigent, S. Bala, A. Barnett, P. Bell, S. Bews, Born Gvr., J. Branagan, N. Brooks, M. Brown, N. Browse, R. Capildeo, M. Carmalt, A. Carter, I. Chalmers, M. Clarke, R. Clarke, Clyne Cac., R. Collins, Cooke, G. Coutts, D. Cove, P. Crowther, W. Cuthbertson, D. Debono, C. Dickerson, J. Dickinson, R. Doll, J. Dormandy, D. Dunbabin, S. Ell, P. Elphinstone, P. Elwood, V. Englishby, B. Farrell, C. Fiskerstrand, M. Flather, T. Foley, T. Foulds, K. Fox, P. Franks, H. Fraser, T. Gardecki, M. Gawel, A. Gent, A. Gershlick, J. Godwin, M. Goldman, C. Gray, D. Gray, R. Gray, H. Handoll, G. Hankey, Harrison Mjg., N. Henderson, S. Heptinstall, S. Hobbiger, E. Jones, Jones Nag., S. Jost, D. Julian, J. Kellett, R. Kester, G. Lowe, J. Mackenzie, C. McCollum, G. Mead, T. Meade, D. Mendelow, J. Miller, G. Morris, C. Nichol, M. Noble, Obrien, M. Ogier, S. Parish, M. Parry, R. Peto, J. Powell, P. Pozzilli, N. Qizilbash, A. Rahman, S. Rajah, D. Richards, S. Richards, R. Ripley, V. Roberts, F. Rose, Russell Rwr., P. Rubin, C. Ruckley, P. Sandercock, Shaw Mdm., K. Shaw, J. Shelley, J. Slattery, P. Sleight, S. Smith, P. Stewartlong, P. Sweetnam, Tansey Mjb., H. Tindall, J. Turney, H. Tyler, N. Varey, M. Vessey, M. Walker, M. Walker, C. Warlow, R. Wilcox, H. Willems, E. Wood, E. Wynjones, H. Adams, B. Barton, R. Bedford, B. Bick, S. Bingham, B. Brown, T. Bryant, J. Buring, C. Cabot, P. Canner, J. Chesebro, O. Chrisman, G. Clagett, J. Colwell, M. Dyken, D. Ellis, W. Fields, C. Furberg, V. Fuster, S. Goldman, J. Granett, R. Green, D. Green, R. Hardy, L. Harker, W. Harris, R. Hart, W. Hass, C. Hennekens, D. Hill, M. Hume, M. Igloe, G. Johnson, S. Jonas, G. Knatterud, T. Kohler, N. Lembo, D. Lewis, E. Lockhart, P. Majerus, Mcenany, R. McKenna, J. Mehta, J. Meyer, B. Molony, T. Moritz, D. Nicoloff, G. Nycz, H. Ono, G. Pantely, S. Phillips, P. Ridker, J. Robertson, R. Rothbart, E. Salzman, R. Sautter, R. Schlant, J. Schoenberger, M. Sengekontacket, G. Sharma, P. Steele, K. Steinnagel, J. Stratton, J. Sullivan, G. Timmis, J. Toole, Walker, S. Weisman, C. White, M. Wirecki, D. Wombolt, R. Wong, S. Yusuf, K. Zadina, D. Zucker (1994)

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

BMJ, 308

D. Clement (1996)

A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

The Lancet, 348

S. Mousa, J. Bozarth, M. Forsythe, A. Slee (2000)

Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.

Cardiovascular research, 47 4

Shaker Mousa, Sandeep Khurana, M. Forsythe (2000)

Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.

Arteriosclerosis, thrombosis, and vascular biology, 20 4

Epilog Investigators (1997)

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

The New England journal of medicine, 336 24

D. Kereiakes, Neal Kleiman, James Ferguson, A. Masud, T. Broderick, C. Abbottsmith, J. Runyon, Linda Anderson, Robert Anders, Roger Dreiling, Gary Hantsbarger, Brian Bryzinski, E. Topol (1998)

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.

Circulation, 98 13

D. Vorchheimer, Valentin Fuster (1998)

Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.

Circulation, 97 4

H. Pieniaszek, S. Sy, W. Ebling, M. Fossler, V. Cain, J. Mondick, Su-Ping Ma, D. Kornhauser (2002)

Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers

The Journal of Clinical Pharmacology, 42

M.A. Creager (1998)

Results of the CAPRIE trial: efficacy and safety of ciopidogrel. Ciopidogrel versus aspirin in patients at risk of ischaemic events

Vasc Med, 3

D. Kereiakes, S. Kleinman, J. Eerguson (1998)

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein iib/iiia receptor blockade with oral xemlofiban

Circulation, 98

C. Heeschen, C. Hamm, Jens Bruemmer, M. Simoons (2000)

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.

Journal of the American College of Cardiology, 35 6

M. Dennis (1996)

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

The Lancet, 348

W. O’Neill, P. Serruys, M. Knudtson, G. Es, G. Timmis, C. Zwaan, J. Kleiman, J. Gong, E. Roecker, R. Dreiling, J. Alexander, R. Anders (2000)

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.

The New England journal of medicine, 342 18

E. Topol, R. Califf, R. Simes, F. Werf, R. Díaz, E. Paoloasso, P. Aylward, A. Keech, W. Klein, L. Piegas, I. Tomov, P. Armstrong, P. Widimsky, P. Grande, M. Halinen, A. Vahanian, K. Neuhaus, A. Dimas, H. White, I. Préda, A. Kristinsson, D. Ardissino, D. Tzivoni, S. Madsen, D. Sugrue, Z. Sadowski, R. Seabra‐Gomes, E. Apetrei, A. Dalby, A. Betriu, M. Pfisterer, F. Verheugt, K. Fox, E. Bates, W. Gibler, C. Granger, R. Harrington, J. Hochman, D. Holmes, N. Kleiman, Kerry Lee, D. Molietrno, L. Newby, E. Ohman (2000)

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial

The Lancet, 355

S. Mousa, T.M. Reilly (1995)

Cardiovascular disease: celiular and molecular mechanisms, prevention, treatment

D. Kereiakes (1999)

Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?

American heart journal, 138 1 Pt 2

S. Mousa, J. Bozarth, U. Naik, A. Slee (2001)

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban

British Journal of Pharmacology, 133

P. Théroux (1998)

Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities.

American heart journal, 135 5 Pt 2 Su

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

References (41)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies